The expanding landscape of ADC targets in CRC now includes not only antigens on bulk tumor cells (CEACAM5, HER2), but also those on cancer stem cells (LGR5) and critical stromal components (CEACAM6), offering multiple avenues to dismantle the tumor ecosystem. Here, CEACAM6 is linked to neoplasm.